Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.

Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.

Biogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.

Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.

Symeres has partnered with Ambagon Therapeutics on molecular glue research in colorectal cancer to target diseases considered hard to treat.

At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key ...

A lack of effective non-invasive ways to diagnose endometriosis contributes to delayed intervention and limits the potential for clinical development of therapeutics. Credit: H_Ko/Shutterstock.com.

At the 2026 ACC Scientific Session in New Orleans, researchers presented a meta-analysis of three randomized trials (1,264 ...

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

Novo Nordisk has received FDA approval for Awiqli injection 700 units/mL, a basal insulin for adults with type 2 diabetes.

Blackstone says this is the largest private life sciences fund ever raised, which will support innovation in pharma and medtech.

In this Q&A with Grace Breen, SVP, Quality, Sharp, we explore the defining moments that have shaped her understanding of what ...